Veteran healthcare executive to drive international growth, strategic partnerships, and global commercialization of the company's molecular diagnostics portfolio
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Industry veteran with over two decades of experience to lead expansion across India, South Asia, Southeast Asia, and other high-growth healthcare markets
Highlights India’s advances in pharmacopoeial science, regulatory standards, and global harmonization efforts at the 16th International Meeting of World Pharmacopoeias
Mahler brings more than 20 years of leadership experience spanning cell therapy, biopharmaceutical development, manufacturing, and global business management
Generic launch targets a US$19 million market in United States, strengthening Glenmark’s institutional and injectable product portfolio in North America
Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination
Report reveals growing confidence in AI-driven decision-making, but highlights persistent challenges in scaling digital investments and converting innovation into measurable business value
Market grows 12.1%; volume contribution improves as 9 out of 10 key therapies post double-digit growth
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Subscribe To Our Newsletter & Stay Updated
